Interferon Alfa News and Research

RSS

Sunitinib shows promise in treating metastatic renal cell cancer

A new study suggests that sunitinib is a promising agent for treatment of metastatic renal cell cancer, currently a disease without highly effective treatment options, according to an article in the June 7 issue of the Journal of the American Medical Association.

7 Jun 2006

Largest U.S. hepatitis C trial yields treatment insights

Community-Based WIN-R Study Shows Significantly Better Outcomes with Weight-Based Dosing

24 May 2006

Largest hepatitis-C U.S. study defines optimal therapy

Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.

14 Nov 2005

Interferon combined with ribavirin treatment is effective for children with chronic Hepatitis C virus

Nearly half of 118 children with chronic Hepatitis C virus (HCV) treated with a combination of interferon-alpha-2b and an optimized dose of ribavirin achieved sustained viral response, and side effects were generally mild.

3 Nov 2005

Intralesional immunotherapy for common warts is effective and safe

Injection of skin test antigens (preparations used in skin tests for immunity) into warts appears to stimulate the immune system and successfully treat the injected wart and also helps to treat distant non-injected warts, according to a study in the May issue of Archives of Dermatology.

16 May 2005

Viramidine demonstrates anti-HCV Genotype 1 activity that compares favorably to Ribavirin

Dose-limiting anemia can be a prominent adverse event of therapy with pegylated interferon and ribavirin. This dose-ranging study examined whether viramidine, a liver-targeting prodrug of ribavirin, may be a safer alternative when used in combination with pegylated interferon alfa-2a/ PEG-IFN (Pegasys).

23 Apr 2005

Vaccine that boosts the immune response could improve the effect of conventional treatment for patients with chronic myeloid leukaemia

CML is caused by the breakage and swapping of chromosomes 9 and 22, which results in a shortened chromosome called the Philadelphia chromosome. Cells with the abnormal chromosome make a protein that encourages aberrant growth and division. Patients with CML can be treated with a drug called imatinib or interferon alfa.

20 Feb 2005

Pegylated interferon alfa-2b offers the best treatment option for people with chronic hepatitis B infection

Harry Janssen (Erasmus University Medical Centre, Rotterdam, Netherlands) and colleagues assessed whether combination treatment with pegylated interferon alfa-2b and the antiviral agent lamivudine was more efficacious in treating chronic hepatitis B infection than pegylated interferon alfa-2b therapy alone.

7 Jan 2005

New approaches for the treatment of chronic hepatitis C

Data from two ongoing studies testing new approaches for the treatment of chronic hepatitis C was presented at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) this afternoon.

1 Nov 2004

Neck surgeons brush up on West Nile virus

Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

17 Sep 2004

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

An international study with nearly 900 patients co-infected with Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV) has shown that HCV can be treated effectively and safely, without compromising the patient’s HIV therapy.

29 Jul 2004

50,000 people in the U.S. with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery

50,000 people or 10% of the 500,000 people in the U.S with cancer, multiple sclerosis, rheumatoid arthritis or hepatitis C will be eligible for a Medicare drug lottery for coverage of life saving drugs.

26 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Largest study comparing leading hepatitis C treatments

Medical centers, hospitals, clinics and other treatment sites across the country are actively enrolling Americans with the hepatitis C virus (HCV) in a nationwide study that will for the first time determine which of the two FDA-approved pegylated interferon therapy regimens offers patients the best chance to eliminate the virus.

14 May 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004